Imaging and biodistribution of radiolabeled SP90 peptide in BT-483 tumor bearing mice.

Abstract

The objective of this study was to evaluate radiolabeled DOTA-SP90 as a radiotracer for breast cancer. The in vitro competition assay showed that radiolabeled DOTA-SP90 had significant binding affinity to BT-483 cancer cells. Biodistribution, nanoSPECT/CT and nanoPET/CT imaging results indicated that radiolabeled DOTA-SP90 can accumulate in tumors. In addition, radiolabeled DOTA-SP90 peptides can also detect metastatic tumors. Therefore, radiolabeled SP90 peptide may provide the potential capability as diagnostic agent for breast cancer patients.

• Authors: Wei-Lin Lo, Chen-Hsien Liang, Liang-Cheng Chen, Shih-Ying Lee, Sheng-Nan Lo, Ming-Wei Chen, Ruei-Min Lu, I-Ju Liu, Han-Chung Wu, Chih-Hsien Chang
• Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine (Appl Radiat Isot) Vol. 161 Pg. 109162 (Jul 2020) ISSN: 1872-9800 [Electronic] England
• PMID: 32561130 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 Elsevier Ltd. All rights reserved.

Chemical References

• Gallium Radioisotopes
• Heterocyclic Compounds, 1-Ring
• Indium Radioisotopes
• Oligopeptides
• Radiopharmaceuticals
• SP90 peptide
• 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid

Topics

• Animals
• Breast Neoplasms (diagnosis, metabolism)
• Cell Line, Tumor
• Female
• Gallium Radioisotopes (pharmacokinetics)
• Heterocyclic Compounds, 1-Ring (metabolism)
• Humans
• Indium Radioisotopes (pharmacokinetics)
• Mice
• Mice, Inbred NOD
• Mice, SCID
• Multimodal Imaging
• Oligopeptides (chemistry, pharmacokinetics)
• Radiopharmaceuticals (chemistry, pharmacokinetics)
• Tissue Distribution
• Xenograft Model Antitumor Assays